iberdomide + daratumumab and hyaluronidase-fihj + dexamethasone

The combination of ZENBEXUS (iberdomide), daratumumab and hyaluronidase-fihj, and dexamethasone (abbreviated as ZDd or IberDd) is an FDA-approved regimen for the treatment of adult patients with relapsed or refractory multiple myeloma. Iberdomide is a first-in-class oral cereblon E3 ligase modulatory drug (CELMoD) that acts as a molecular glue to promote the proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), which are essential for myeloma cell survival. Daratumumab is a human IgG1 monoclonal antibody targeting CD38 on myeloma cells, and hyaluronidase-fihj is a recombinant human hyaluronidase that facilitates subcutaneous administration. Dexamethasone is a corticosteroid that provides synergistic anti-myeloma and anti-inflammatory activity. The regimen received accelerated approval in August 2026 based on minimal residual disease (MRD)-negative complete response rates demonstrated in the Phase 3 EXCALIBER-RRMM trial.

Other names

IberDdIberDd regimenZDdZDd regimenZENBEXUS + daratumumab and hyaluronidase-fihj + dexamethasoneZenbexus + Darzalex Faspro + dexamethasoneiberdomide + daratumumab + hyaluronidase + dexamethasoneiberdomide + daratumumab/hyaluronidase + dexamethasone